Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–86.
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. (2014). Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63:844–55.
   PubMed Web of Science ®Google Scholar
• Yang JD, Kim B, Sanderson SO, et al. (2012). Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc 87:9–16.
   PubMed Web of Science ®Google Scholar
• Yang JD, Roberts LR. (2010). Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7:448–58.
   PubMed Web of Science ®Google Scholar
• Tiong L, Maddern GJ. (2011). Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 98:1210–24.
   PubMed Web of Science ®Google Scholar
• Wang JH, Wang CC, Hung CH, et al. (2012). Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 56:412–18.
   PubMed Web of Science ®Google Scholar
• Cho YK, Kim JK, Kim MY, et al. (2009). Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49:453–9.
   PubMed Web of Science ®Google Scholar
• Harrison LE, Koneru B, Baramipour P, et al. (2003). Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 197:759–64.
   PubMed Web of Science ®Google Scholar
• Kei SK, Rhim H, Choi D, et al. (2008). Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol 190:1544–51.
   PubMed Web of Science ®Google Scholar
• Liu CH, Arellano RS, Uppot RN, et al. (2010). Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression. Eur Radiol 20:877–85.
   PubMed Web of Science ®Google Scholar
• Thompson SM, Callstrom MR, Jondal DE, et al. (2016). Heat stress-induced PI3K/mTORC2-dependent AKT signaling is a central mediator of hepatocellular carcinoma survival to thermal ablation induced heat stress. PLoS One 11:e0162634.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran R, Venkatesh SK, Torbenson M, Roberts LR. (2016). Clinical implications of basic research in hepatocellular carcinoma. J Hepatol 64:736–45.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. (2010). Cell signaling by receptor tyrosine kinases. Cell 141:1117–34.
   PubMed Web of Science ®Google Scholar
• Casaletto JB, McClatchey AI. (2012). Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer 12:387–400.
   PubMed Web of Science ®Google Scholar
• Breuhahn K, Longerich T, Schirmacher P. (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25:3787–800.
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signalling. Nature 411:355–65.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Toffanin S, Lachenmayer A, et al. (2010). Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30:35–51.
   PubMed Web of Science ®Google Scholar
• You H, Ding W, Dang H, et al. (2011). c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54:879–89.
   PubMed Web of Science ®Google Scholar
• Wu F, Wu L, Zheng S, et al. (2006). The clinical value of hepatocyte growth factor and its receptor-c-met for liver cancer patients with hepatectomy. Dig Liver Dis 38:490–7.
   PubMedGoogle Scholar
• Kaposi-Novak P, Lee JS, Gomez-Quiroz L, et al. (2006). Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–95.
   PubMed Web of Science ®Google Scholar
• Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, et al. (2012). Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57:108–15.
   PubMed Web of Science ®Google Scholar
• Berasain C, Nicou A, Garcia-Irigoyen O, et al. (2012). Epidermal growth factor receptor signaling in hepatocellular carcinoma: inflammatory activation and a new intracellular regulatory mechanism. Dig Dis 30:524–31.
   PubMed Web of Science ®Google Scholar
• Ezzoukhry Z, Louandre C, Trecherel E, et al. (2012). EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 131:2961–9.
   PubMed Web of Science ®Google Scholar
• Thompson SM, Callstrom MR, Butters KA, et al. (2014). Heat stress induced cell death mechanisms in hepatocytes and hepatocellular carcinoma: in vitro and in vivo study. Lasers Surg Med 46:290–301.
   PubMed Web of Science ®Google Scholar
• Thompson SM, Callstrom MR, Butters KA, et al. (2014). Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study. Cardiovasc Intervent Radiol 37:1343–51.
   PubMed Web of Science ®Google Scholar
• Rush J, Moritz A, Lee KA, et al. (2005). Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23:94–101.
   PubMed Web of Science ®Google Scholar
• Stokes MP, Farnsworth CL, Moritz A, et al. (2012). PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS. Mol Cell Proteomics 11:187–201.
   PubMed Web of Science ®Google Scholar
• Stokes MP, Farnsworth CL, Gu H, et al. (2015). Complementary PTM profiling of drug response in human gastric carcinoma by immunoaffinity and IMAC methods with total proteome analysis. Proteomes 3:160–83.
   PubMed Web of Science ®Google Scholar
• Kramer A, Green J, Pollard J, Jr, Tugendreich S. (2014). Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30:523–30.
   PubMed Web of Science ®Google Scholar
• Thompson SM, Callstrom MR, Knudsen B, et al. (2012). Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations. J Vasc Interv Radiol 23:385–95.
   PubMed Web of Science ®Google Scholar
• Thompson SM, Callstrom MR, Knudsen BE, et al. (2013). Molecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma. Invest Radiol 48:413–21.
   PubMed Web of Science ®Google Scholar
• Thompson SM, Callstrom MR, Knudsen B, et al. (2013). AS30D model of hepatocellular carcinoma: tumorigenicity and preliminary characterization by imaging, histopathology, and immunohistochemistry. Cardiovasc Intervent Radiol 36:198–203.
   PubMed Web of Science ®Google Scholar
• Sattler M, Pride YB, Ma P, et al. (2003). A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63:5462–9.
   PubMed Web of Science ®Google Scholar
• Bulgaru AM, Mani S, Goel S, Perez-Soler R. (2003). Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther 3:269–79.
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Lee JH, et al. (2012). Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther 11:1036–47.
   PubMed Web of Science ®Google Scholar
• Pandey A, Lazar DF, Saltiel AR, Dixit VM. (1994). Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J Biol Chem 269:30154–7.
   PubMed Web of Science ®Google Scholar
• Efazat G, Novak M, Kaminskyy VO, et al. (2016). Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer. Oncotarget 7:60332–47.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Factor VM, Marquardt JU, et al. (2012). Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology 55:1215–26.
   PubMed Web of Science ®Google Scholar
• Huh CG, Factor VM, Sanchez A, et al. (2004). Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101:4477–82.
   PubMed Web of Science ®Google Scholar
• Ueki T, Fujimoto J, Suzuki T, et al. (1997). Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25:619–23.
   PubMed Web of Science ®Google Scholar
• Tavian D, De Petro G, Benetti A, et al. (2000). u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer 87:644–9.
   PubMed Web of Science ®Google Scholar
• Goyal L, Muzumdar MD, Zhu AX. (2013). Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 19:2310–18.
   PubMed Web of Science ®Google Scholar
• Jagoda EM, Lang L, Bhadrasetty V, et al. (2012). Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J Nucl Med 53:1592–600.
   PubMed Web of Science ®Google Scholar